Table 2. Oligonucleotides used in this study.

Primer	Sequence	Accession number and corresponding sequence (nt)
BSAB-BamHI-F	5′-cgcggaTCCGCGACCTCTTGCTTCCGACA-3′	Z99111 (23924–23902 (minus strand))
BSpAB-BAPS-F	5′-AAAAAAGGATTTGGTGAAAACTATGAAAAAGCTAGATCTGATGA-3′	Z99111 (23633–23609 (minus strand))
		JN561694 (1458–1480)
BSpAB-BAPS-R	5′-TCATCAGATCTAGCTTTTTCATAGTTTTCACCAAATCCTTTTTT-3′	JN561694 (1480–1458 (minus strand))
		Z99111 (23609–23633)
BAPS-SphI-R	5′-acAtgcAtgCCCAAGGAATATTGTCTCCTCG-3′	JN561694 (3020–2999 (minus strand))
PS(BA)-S-M33L-F	5′-ATGACGTTGATTTTAGTGTTTTTTGTTcTGTTATTTTCGATGTCAGAAAT-3′	JN561694 (2326–2375)
PS(BA)-S-M33L-R	5′-AAAAAACACTAAAATCAACGTCAT-3′	JN561694 (2349–2326 (minus strand))
BAPS-NcoI-F	5′-catGccatggATGAAAAAGCTAGATCTGATGACA-3′	JN561694 (1458–1481)
BAPS-PstI-R	5′-aaaaCtGcagTTAATAAGTATCATCCTCTTCATA-3′	JN561694 (2994–2971 (minus strand))

Extra nucleotides that were added to introduce restriction sites are underlined.

Substituted nucleotides that were added to introduce point mutation sites are shown by a small letter.